Pembrolizumab,Vibostolimab,Gebasaxturev,MK-4830,Favezelimab
Merck
['vibostolimab', 'gebasaxturev', 'melanoma', 'pembro']
#cedarssinaicancer at #aacr23. dr. inderjit mehmi is co-author on keymaker-u02 substudy 02c: neoadjuvant pembrolizumab + vibostolimab or gebasaxturev or pembro alone followed by adjuvant pembro for stage iiib-d #melanoma presented at 10:15am pt. 
Cedars-Sinai Cancer, ranked #9 in the nation in 2021 by U.S. News & World Report.